About Xintela
About the company
Xintela is a publicly-traded clinical-stage biopharma company developing cutting edge medical products in stem cell therapy and targeted cancer therapy. Xintela’s proprietary technology uses the stem cell marker integrin α10β1 to select and quality-assure stem cells in the product XSTEM®, which has shown safety and positive efficacy in a clinical study on knee osteoarthritis and has completed a clinical study on difficult-to-heal leg ulcers. Xintela’s in-house GMP-facility manufactures XSTEM® and provides process development and manufacturing of other cell therapies.
Xintela’s wholly owned subsidiary Targinta AB develops First-in-Class therapeutic antibodies targeting integrin α10β1. TARG9, an Antibody-Drug Conjugate (ADC), and TARG10, a function blocking antibody, are in preclinical development for the treatment of aggressive, difficult to treat cancers including glioblastoma, triple-negative breast cancer and sarcoma.
Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm under the symbol XINT.
Key milestones
2009
Xintela was founded by the company’s CEO Evy Lundgren-Åkerlund. The company’s operations are based on many years of research and development at Lund University and in the company Cartela AB.
2013
Xintela’s research and development activities were established at Medicon Village in Lund, with a focus on development of stem cell products for the treatment of osteoarthritis.
2017
EQSTEM® demonstrated safety and efficacy in a preclinical osteoarthritis study in horses in collaboration with Cornell University.
2021
Xintela obtained a license for the manufacture of stem cell products in the company’s own GMP facility and produced the first XSTEM® product for clinical studies.
2022
Clinical studies started with XSTEM® on knee osteoarthritis and on difficult-to-heal venous leg ulcers.
2023
XSTEM® demonstrated safety and positive efficacy data in a preclinical study on ARDS (acute respiratory distress syndrome) in collaboration with Skåne University Hospital.
2025
Xintela signed a collaboration and license agreement with EQGen Biomedical for the clinical development and commercialization of EQSTEM® and stem cell products for other animals.
2025
XSTEM® demonstrated safety and positive efficacy data in knee osteoarthritis supporting disease modifying effect.
Intellectual Property
Xintela has built a robust IP position around its integrin α10β1 platform with six patent families and over 85 active patents and patent applications across more than 30 jurisdictions, including the US, Europe, Japan, China, Australia, and key emerging markets.
The portfolio secures exclusivity over the XSTEM® product, integrin α10-based cell selection and quality assurance methods, and therapeutic applications in e.g. bone and cartilage disorders, respiratory conditions, and wound healing. The portfolio includes numerous granted patents in all major markets, continues to grow through new filings, and provides protection into the 2040s with potential for patent term extensions. Freedom-To-Operate (FTO) assessments covering the platform are conducted and maintained on an ongoing basis.
Key brands including XSTEM®, XINTELA®, XACT®, EQSTEM®, and CANISTEM® are registered trademarks.
Strategy
Xintela’s strategy is to make XSTEM® the leading stem cell therapy platform for the treatment of osteoarthritis, difficult to heal wounds and other indications, through partnering and licensing.
Targinta’s strategy is to achieve clinical proof-of-concept with the drug candidates TARG9 and TARG10 for the treatment of aggressive cancer, through partnering and licensing.
Patent portfolio
Xintela has a broad and strong patent portfolio that includes over 50 approved patents in key markets such as Australia, Europe, Canada, Japan and the USA.
Patentportfölj behöver uppdateras!
